Nuvation Bio Inc.
NUVB US67080N1019
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Markel Stacy SR OFF |
1.71 USD |
10,000 Bought |
17,100 USD |
18/06/2025 | 18/06/2025 |
| Markel Stacy SR OFF |
1.71 USD |
10,000 Bought |
17,100 USD |
18/06/2025 | 18/06/2025 |
| Sauvage Philippe CFO |
1.79 USD |
4,000 Bought |
7,160 USD |
16/06/2025 | 17/06/2025 |
| Sauvage Philippe CFO |
1.79 USD |
4,000 Bought |
7,160 USD |
16/06/2025 | 17/06/2025 |
| Wentworth Kerry SR OFF |
1.80 USD |
24,000 Bought |
43,200 USD |
16/06/2025 | 16/06/2025 |
| Wentworth Kerry SR OFF |
1.80 USD |
24,000 Bought |
43,200 USD |
16/06/2025 | 16/06/2025 |
| Wentworth Kerry SR OFF |
1.79 USD |
26,000 Bought |
46,540 USD |
16/06/2025 | 16/06/2025 |
| Sjogren Colleen CCO |
1.81 USD |
50,000 Bought |
90,350 USD |
16/06/2025 | 16/06/2025 |
| Sauvage Philippe CFO |
1.84 USD |
3,300 Bought |
6,056 USD |
16/06/2025 | 16/06/2025 |
| Hung David CEO |
1.79 USD |
500,000 Bought |
893,500 USD |
16/06/2025 | 16/06/2025 |